Bispecific Antibody Provides Durable Remission in Myeloma

ORLANDO, Florida — For patients with heavily pretreated relapsed or refractory multiple myeloma, use of a novel bi-specific antibody designed to minimize the cytokine release syndrome (CRS) was associated with deep and durable clinical responses, and the safety profile was an acceptable. The findings come from a first-in-human phase 1/2…Read More